CA2396351A1 - Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques - Google Patents
Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques Download PDFInfo
- Publication number
- CA2396351A1 CA2396351A1 CA002396351A CA2396351A CA2396351A1 CA 2396351 A1 CA2396351 A1 CA 2396351A1 CA 002396351 A CA002396351 A CA 002396351A CA 2396351 A CA2396351 A CA 2396351A CA 2396351 A1 CA2396351 A1 CA 2396351A1
- Authority
- CA
- Canada
- Prior art keywords
- antipsychotic
- antipsychotic agent
- dioxino
- indol
- benzylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000028017 Psychotic disease Diseases 0.000 title claims abstract 7
- 230000002265 prevention Effects 0.000 title abstract 3
- 238000011282 treatment Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000000164 antipsychotic agent Substances 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 8
- DYJIKHYBKVODAC-ZDUSSCGKSA-N (2s)-2-[(benzylamino)methyl]-2,3,7,9-tetrahydro-[1,4]dioxino[2,3-e]indol-8-one Chemical compound C([C@H]1COC=2C=CC3=C(C=2O1)CC(N3)=O)NCC1=CC=CC=C1 DYJIKHYBKVODAC-ZDUSSCGKSA-N 0.000 claims 7
- 230000000561 anti-psychotic effect Effects 0.000 claims 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 6
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 3
- KLPWJLBORRMFGK-UHFFFAOYSA-N Molindone Chemical compound O=C1C=2C(CC)=C(C)NC=2CCC1CN1CCOCC1 KLPWJLBORRMFGK-UHFFFAOYSA-N 0.000 claims 3
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 3
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims 3
- GFBKORZTTCHDGY-UWVJOHFNSA-N Thiothixene Chemical compound C12=CC(S(=O)(=O)N(C)C)=CC=C2SC2=CC=CC=C2\C1=C\CCN1CCN(C)CC1 GFBKORZTTCHDGY-UWVJOHFNSA-N 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 239000003693 atypical antipsychotic agent Substances 0.000 claims 3
- 229940127236 atypical antipsychotics Drugs 0.000 claims 3
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical group C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 3
- 229960001076 chlorpromazine Drugs 0.000 claims 3
- 229960004170 clozapine Drugs 0.000 claims 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 3
- 229960002690 fluphenazine Drugs 0.000 claims 3
- 229960003878 haloperidol Drugs 0.000 claims 3
- 229960000423 loxapine Drugs 0.000 claims 3
- XJGVXQDUIWGIRW-UHFFFAOYSA-N loxapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2OC2=CC=C(Cl)C=C12 XJGVXQDUIWGIRW-UHFFFAOYSA-N 0.000 claims 3
- SLVMESMUVMCQIY-UHFFFAOYSA-N mesoridazine Chemical compound CN1CCCCC1CCN1C2=CC(S(C)=O)=CC=C2SC2=CC=CC=C21 SLVMESMUVMCQIY-UHFFFAOYSA-N 0.000 claims 3
- 229960000300 mesoridazine Drugs 0.000 claims 3
- 229960004938 molindone Drugs 0.000 claims 3
- 229960005017 olanzapine Drugs 0.000 claims 3
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 3
- 229960000762 perphenazine Drugs 0.000 claims 3
- ZTHJULTYCAQOIJ-WXXKFALUSA-N quetiapine fumarate Chemical compound [H+].[H+].[O-]C(=O)\C=C\C([O-])=O.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12.C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 ZTHJULTYCAQOIJ-WXXKFALUSA-N 0.000 claims 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 3
- 229960001534 risperidone Drugs 0.000 claims 3
- 229940035004 seroquel Drugs 0.000 claims 3
- 229960002784 thioridazine Drugs 0.000 claims 3
- 229960005013 tiotixene Drugs 0.000 claims 3
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 claims 3
- 229960002324 trifluoperazine Drugs 0.000 claims 3
- 208000022610 schizoaffective disease Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des combinaisons thérapeutiques, utiles dans le traitement ou la prévention de troubles psychotiques; elle concerne également des compositions pharmaceutiques contenant ces combinaisons, ainsi que l'utilisation de celles-ci dans le traitement ou la prophylaxie de troubles psychotiques.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45860799A | 1999-12-10 | 1999-12-10 | |
| US09/458,607 | 1999-12-10 | ||
| PCT/US2000/033060 WO2001041750A2 (fr) | 1999-12-10 | 2000-12-07 | Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2396351A1 true CA2396351A1 (fr) | 2001-06-14 |
| CA2396351C CA2396351C (fr) | 2009-11-10 |
Family
ID=23821437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002396351A Expired - Lifetime CA2396351C (fr) | 1999-12-10 | 2000-12-07 | Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1235570A2 (fr) |
| JP (1) | JP5557409B2 (fr) |
| KR (1) | KR100772854B1 (fr) |
| CN (1) | CN1230164C (fr) |
| AR (1) | AR026756A1 (fr) |
| AU (1) | AU784211B2 (fr) |
| BR (1) | BR0016168A (fr) |
| CA (1) | CA2396351C (fr) |
| CZ (1) | CZ20021880A3 (fr) |
| EA (1) | EA005002B1 (fr) |
| HK (1) | HK1045942A1 (fr) |
| HU (1) | HUP0203309A3 (fr) |
| IL (2) | IL149669A0 (fr) |
| MX (1) | MXPA02005649A (fr) |
| NO (1) | NO20022739D0 (fr) |
| NZ (1) | NZ519381A (fr) |
| PL (1) | PL355292A1 (fr) |
| TW (1) | TWI222864B (fr) |
| WO (1) | WO2001041750A2 (fr) |
| ZA (1) | ZA200205484B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101409724B1 (ko) | 2003-10-29 | 2014-06-19 | 와이어쓰 엘엘씨 | 아플린도어 및 이의 유도체를 포함하는 서방성 약제학적조성물 |
| JP2008530229A (ja) | 2005-02-17 | 2008-08-07 | ワイス | シクロアルキル縮合インドール、ベンゾチオフェン、ベンゾフランおよびインデン誘導体 |
| ES2430622T3 (es) * | 2008-02-13 | 2013-11-21 | Targacept, Inc. | Combinación de agonistas nicotínicos alfa 7 y antipsicóticos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
| US5756532A (en) * | 1995-11-06 | 1998-05-26 | American Home Products Corporation | Aminomethyl-2 3 8 9-tetrahydro-7H-1 4-dioxino 2 3-E!-indol-8-ones and derivatives |
| GB9627005D0 (en) * | 1996-12-27 | 1997-02-12 | Knoll Ag | Therapeutic agents |
-
2000
- 2000-12-07 EA EA200200656A patent/EA005002B1/ru not_active IP Right Cessation
- 2000-12-07 NZ NZ519381A patent/NZ519381A/en unknown
- 2000-12-07 WO PCT/US2000/033060 patent/WO2001041750A2/fr active IP Right Grant
- 2000-12-07 BR BR0016168-3A patent/BR0016168A/pt not_active Application Discontinuation
- 2000-12-07 CZ CZ20021880A patent/CZ20021880A3/cs unknown
- 2000-12-07 EP EP00982461A patent/EP1235570A2/fr not_active Withdrawn
- 2000-12-07 AU AU19490/01A patent/AU784211B2/en not_active Ceased
- 2000-12-07 CN CNB008169527A patent/CN1230164C/zh not_active Expired - Lifetime
- 2000-12-07 IL IL14966900A patent/IL149669A0/xx active IP Right Grant
- 2000-12-07 HU HU0203309A patent/HUP0203309A3/hu unknown
- 2000-12-07 PL PL00355292A patent/PL355292A1/xx not_active Application Discontinuation
- 2000-12-07 MX MXPA02005649A patent/MXPA02005649A/es active IP Right Grant
- 2000-12-07 AR ARP000106504A patent/AR026756A1/es unknown
- 2000-12-07 JP JP2001543095A patent/JP5557409B2/ja not_active Expired - Lifetime
- 2000-12-07 KR KR1020027007286A patent/KR100772854B1/ko not_active IP Right Cessation
- 2000-12-07 CA CA002396351A patent/CA2396351C/fr not_active Expired - Lifetime
- 2000-12-08 TW TW089126071A patent/TWI222864B/zh not_active IP Right Cessation
-
2002
- 2002-05-15 IL IL149669A patent/IL149669A/en not_active IP Right Cessation
- 2002-06-07 NO NO20022739A patent/NO20022739D0/no not_active Application Discontinuation
- 2002-07-09 ZA ZA200205484A patent/ZA200205484B/xx unknown
- 2002-10-09 HK HK02107378.5A patent/HK1045942A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU1949001A (en) | 2001-06-18 |
| PL355292A1 (en) | 2004-04-05 |
| MXPA02005649A (es) | 2004-09-10 |
| WO2001041750A3 (fr) | 2002-02-14 |
| KR100772854B1 (ko) | 2007-11-02 |
| IL149669A0 (en) | 2002-11-10 |
| IL149669A (en) | 2006-06-11 |
| ZA200205484B (en) | 2003-12-31 |
| CN1230164C (zh) | 2005-12-07 |
| JP5557409B2 (ja) | 2014-07-23 |
| HK1045942A1 (zh) | 2002-12-20 |
| EA200200656A1 (ru) | 2002-12-26 |
| CZ20021880A3 (cs) | 2002-08-14 |
| BR0016168A (pt) | 2002-08-20 |
| EP1235570A2 (fr) | 2002-09-04 |
| WO2001041750A2 (fr) | 2001-06-14 |
| AR026756A1 (es) | 2003-02-26 |
| KR20030016207A (ko) | 2003-02-26 |
| JP2003516350A (ja) | 2003-05-13 |
| NO20022739L (no) | 2002-06-07 |
| HUP0203309A3 (en) | 2004-12-28 |
| NZ519381A (en) | 2004-04-30 |
| NO20022739D0 (no) | 2002-06-07 |
| CA2396351C (fr) | 2009-11-10 |
| TWI222864B (en) | 2004-11-01 |
| HUP0203309A2 (hu) | 2003-01-28 |
| EA005002B1 (ru) | 2004-10-28 |
| AU784211B2 (en) | 2006-02-23 |
| CN1409633A (zh) | 2003-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU762481C (en) | Vitamin D and its analogs in the treatment of tumors and other hyperproliferative disorders | |
| EP1243267A3 (fr) | Composition pharmaceutique contenant de l'amoxicilline et du clavulanate | |
| RU2000104121A (ru) | Терапевтические и диетические композиции, содержащие необходимые жирные кислоты и биологически активные дисульфиды | |
| AU681452B2 (en) | Pernasal composition and pernasal preparation containing thesame | |
| TW366286B (en) | Flavour-masked pharmaceutical compositions | |
| IL119627A0 (en) | Controlled-release pharmaceutical preparations | |
| WO2003039436A3 (fr) | Compositions pharmaceutiques contenant de l'oxybutine | |
| AU1099288A (en) | Drug delivery system and method of making the same | |
| WO2001095899A8 (fr) | Compositions pharmaceutiques renfermant des derives de cannabidiol | |
| MY130098A (en) | Local drug delivery film for periodontal treatment | |
| AU2223095A (en) | Effervescent pharmaceutical formulations containing controlled release biodegradable microcapsules | |
| NZ514129A (en) | Tolperison-containing, pharmaceutical preparation for oral administration | |
| BR0013719A (pt) | Dosagem oral de liberaçâo controlada, apropriada para administração oral | |
| US6566389B1 (en) | Therapeutic uses of melatonin | |
| CA2396351A1 (fr) | Nouvelles combinaisons therapeutiques de (s)-2-(benzylamino-methyl)-2,3,8,9,-tetrahydro-7h-1,4-dioxino[2,3-e]indol-8-one et neuroleptiques destines au traitement ou a la prevention de troubles psychotiques | |
| KR100420673B1 (ko) | 지연된구토반응을치료하기위한비강투여제 | |
| ATE212550T1 (de) | Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung | |
| EP1197227A4 (fr) | Procede d'administration de medicaments possedant une affinite de liaison aux proteines plasmatiques et preparation utilisee pour la mise en oeuvre dudit procede | |
| JO2296B1 (en) | Substituted pyrolates | |
| RU2003106417A (ru) | Применение комбинации витаминов для лечения первичных головных болей | |
| CA2336711A1 (fr) | Plaquette alveolaire contenant un systeme therapeutique transdermique et une forme galenique individuelle | |
| WO2013024487A1 (fr) | Composition anti-vitiligo | |
| CZ5821U1 (cs) | Farmaceutický přípravek pro léčení hernofilie a použití hormonu mestranolu | |
| CA2187153A1 (fr) | Formulations pharmaceutiques effervescentes contenant des microgelules biodegradables a liberation controlee | |
| WO2004050019A3 (fr) | Compositions et methode de traitement de l'anxiete |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20201207 |